1DELMAS PD, BJARNASON NH, MITLAK BH, et al.Effects of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in postmenopausal women [J]. New Engl J Med, 1997, 337:1641 - 1647.
2ETTINGER B, BLACK DM, MITLAK BH, et al. For the Multiple Outcomes of Raloxifene Evaluation (MORE) investigator. Reduction of vertebral fracture risk in postmenopausal woman with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial [J].JAMA, 1999, 282: 637-645.
3ANDERSON B, JAHANSSON G, HOLM G, et al.Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes : a randomized clinical trial [J]. Clin Endocrinol Metab,2002, 87 (1) : 122 - 128.
4POLS HA, FELSENBERG D, HANLEY DH, et al, Multinational placebo- controlled, randomized trial of the effects of alendronate on bone mineral density and fracture risk in postmenopausal women with low bone mass: resuits of the FOSIT study [J]. Osteoporosis Int, 1999, 9(5) : 461 - 468.
5BLACK DM, THOMPSON DE, BAUAR DC, et al.Fracture risk reduction with Alendronate in women with osteoporosis: The fracture intervention trial [J]. J Clin Endocrinol Metab, 2000, 85 (1): 4114-4124.
6ORWALL E, ETrINGER M, WEISS S, et al. Alendronate for the treatment of osteoporosis in men [J]. New Engl J Med, 2001, 343: 604-610.
7REGINSTER J, MINNE HW, SORANSON OH, et al.Randomized trial of the effects of risedronate on vertebral fractuce in women with established postmenspausal osteoporosis [J]. Osteoporosis Int, 2000, 11 : 83- 91.
8CHESNICT CH, SILVERMAN S, ANDRIANO K, et al.A ramdomized trial of nasal spray salmon calcitonin in post- menopausal women with established osteoporosis[J]. Am J Med, 2000, 109 (4): 267- 276.
9NEER RM, ARNAUD CD, ZORNCHETFA JR, et al.Effects of parathyroid hormone ( 1 - 34) on fracture and bone mineral density in postmenopausal women with osteoporosis [J]. New Engl J Med, 2001, 344: 1434-1441.
10MORLEY P, WHITFIELD JF, WILLICK GE, et al.Parathyroid hormone: an anabolic treatment for osteoporosis [J]. Curr Pharm Des, 2001, 7 (8): 671-687.
5Delmas PD, Bjarnason NH, Miti K BH et al. Efects of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in postmenopausal women [J] . New Engl J Med, 1997, 337 : 1641-1647.
6Eitinger B, Black DM, Mitiak BH, et al. For the Multiple Outcomes of Raloxifene Evaluation (MORE) investigator. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with ralox.ifene: results from a 3-year randomized clinical trial [J] . JAMA, 1999, 282: 637-645.
7Aderson B, Jahansson G, HolmG, et al. RMoxifene does not affect insulin sensitivity or glycemiccontrol in postmenopausal wome with type 2 diabetes: arandomized clinical trial [J] . Clin Endocrinol Metab, 2002, 87(1) : 122-128.
8夏维波.骨质疏松症治疗进展.中国医学论坛报,2006,:999-999,2001.
9Whitifield JF, Modey P, Ross v, et al. Restoration of severally depleted ferm oralrtabeeular bone in OVX rats by hPTH (1-34) [J] . Calcf Tissue Int, 1995, 56 : 227-231.
10Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism [J]. J Clin Endocrinol Metab. 1995, 80:723.
